MTD Group completes acquisition of Ypsomed's pen needles and BGM businesses

Medical Technology and Devices (MTD) has closed the acquisition of Ypsomed's Pen Needles and Blood Glucose Monitoring Systems businesses. The deal increases MTD's pen needle production capacity to over 2.5 billion units, strengthening its position as the world's #2 player.

“This acquisition marks a major step forward in MTD's mission to provide superior diabetes and obesity care solutions on a global scale.”prnewswire.co.uk

• 1 source
• prnewswire.co.ukMTD Group completes the acquisition of Ypsomed's Pen Needles and Blood Glucose Monitoring Systems and announces a significant investment plan for its European production sitesMTD Medical Technology, DevicesAug 2, 2024

Summarized from public sources; check the original articles before acting on it.